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Abstract
Background: Human cathelicidin LL-37 is a cationic antimicrobial peptide (AMP) which possesses a variety of activities
including the ability to neutralise endotoxin. In this study, we investigated the role of LPS neutralisation in mediating LL-37’s
ability to inhibit Pseudomonas aeruginosa LPS signalling in human monocytic cells.
Methodology/Principal Findings: Pre-treatment of monocytes with LL-37 significantly inhibited LPS-induced IL-8
production and the signalling pathway of associated transcription factors such as NF-kB. However, upon removal of LL-
37 from the media prior to LPS stimulation, these inhibitory effects were abolished. These findings suggest that the ability of
LL-37 to inhibit LPS signalling is largely dependent on extracellular LPS neutralisation. In addition, LL-37 potently inhibited
cytokine production induced by LPS extracted from P. aeruginosa isolated from the lungs of cystic fibrosis (CF) patients. In
the CF lung, polyanionic molecules such as glycosaminoglycans (GAGs) and DNA bind LL-37 and impact negatively on its
antibacterial activity. In order to determine whether such interactions interfere with the LPS neutralising ability of LL-37, the
status of LL-37 and its ability to bind LPS in CF sputum were investigated. Overall our findings suggest that in the CF lung,
the ability of LL-37 to bind LPS and inhibit LPS-induced IL-8 production is attenuated as a result of binding to DNA and
GAGs. However, LL-37 levels and its concomitant LPS-binding activity can be increased with a combination of DNase and
GAG lyase (heparinase II) treatment.
Conclusions/Significance: Overall, these findings suggest that a deficiency in available LL-37 in the CF lung may contribute
to greater LPS-induced inflammation during CF lung disease.
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Introduction
Cystic fibrosis (CF) is an autosomal recessive disease caused by
mutations in the cystic fibrosis transmembrane conductance
regulator (CFTR). Mutated CFTR results in defective electrolyte
transport in the airways which leads to a continual cycle of airway
surface liquid dehydration, airway obstruction, chronic bacterial
infection and airway inflammation [1,2]. Research to date suggests
that mutations in the CFTR gene contribute to the dysregulation
of a variety of components of the innate immune system [3,4].
Antimicrobial peptides (AMPs) play an essential role in the innate
immune system and contribute to host defence through direct
antimicrobial activity, as well as by modulating innate and
adaptive immunity and wound repair [5]. In CF, the antibacterial
capacity of airway fluid is paradoxically low despite the presence of
a high AMP load [6–8]. Levels of one AMP in particular, the
human cathelicidin LL-37, are significantly elevated in CF lung
secretions and levels correlated with disease severity in CF patients
[9,10]. Research to date supports the hypothesis that despite being
present in large quantities in the CF airways, the antimicrobial
activity of LL-37 is markedly restricted although the nature of this
defect in vivo remains unclear.
LL-37 has a broad spectrum of antimicrobial activity acting
against both Gram-positive and Gram-negative bacteria including
Staphylococus aureus and Pseudomonas aeruginosa [11–16]. In addition,
a low concentration of LL-37 (0.5 mg/ml) potently inhibited the
formation of P. aeruginosa biofilm in vitro [17]. As previously
mentioned, the antimicrobial activity of LL-37 is markedly
restricted in the CF lung. The results to date have suggested both
a salt-dependent [6] and -independent [8,15] restriction of
antimicrobial activity. Elevated levels of LL-37 in CF are thought
to be a consequence of increased local production and correlate
with neutrophilia – a characteristic of the CF airways [9,10].
Nevertheless, the anionic poly-electrolytes DNA and filamentous
(F)-actin derived mainly from neutrophils contribute significantly
to viscosity in the CF lung and strongly inhibit the antibacterial
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work has found that the antibacterial activity of LL-37 was
inhibited by a range of molecules including bacterial polysaccha-
rides [20,21], mucins [22,23], proteases [24], in addition to
glycosaminoglycans (GAGs) present in wound fluids [25] and CF
lung secretions [26]. Treatment of CF lung secretions in vitro with
gelsolin, polyanions such as poly-aspartate, DNase and GAG
lyases, and in vivo with nebulised hypertonic saline [19,26] are
reported to increase the levels of LL-37 as well as the bactericidal
activity of samples.
LL-37 possesses activities extending beyond its basic bactericidal
activity and a large body of work has focused on the immu-
nomodulatory activity of LL-37, which may be as, or more,
important than its direct antimicrobial action under physiological
conditions [23,27]. Lipopolysaccharide (LPS) neutralising activities
of LL-37 have been well characterised in vitro and in vivo [28–32].
Although previous research has focussed on the bactericidal
activity of LL-37 in CF lung secretions and its inhibition by
molecules such as DNA and GAGs, the effects of such molecules
on the ability of LL-37 to neutralise/inhibit LPS signalling are
unknown. P. aeruginosa LPS is a prominent factor in mediating both
bacterial virulence and host responses in susceptible individuals
such as CF patients [33]. Therefore, the aim of this study was to
investigate the importance of LPS neutralisation in the anti-
endotoxin activity of LL-37 and to determine the efficacy of this
important biological effect in CF lung secretions.
Materials and Methods
Ethics Statement
Ethical approval was received from the Office for Research
Ethics Northern Ireland (ethical approval study number 06/
NIR01/11) with all patients providing written informed consent
prior to participation.
Materials
Recombinant human LL-37 and rabbit anti-LL-37 were
purchased from Innovagen (Lund, Sweden). Complete protease
inhibitor cocktail tablets were from Roche Diagnostics. LPS from
P. aeruginosa (serotype 10) and heparinase II from Flavobacterium
heparinum were purchased from Sigma-Aldrich, Dorset, UK.
Mouse anti-phospho IkBa (Ser32/36), rabbit anti-IkBa, anti-
phospho IKKa/b (Ser180/181) were purchased from Cell
Signaling Technology, Danvers, Massachusetts, USA. Rabbit
anti-IkBb and anti-GAPDH were purchased from Santa Cruz
Biotechnology, Germany. HRP-conjugated secondary antibodies
were obtained from Thermo Fisher Scientific, Northumberland,
UK. All other reagents were of analytical grade and were
purchased from Sigma-Aldrich unless otherwise stated.
P. aeruginosa LPS Preparation and Mass Spectrometry
Procedures
LPS was extracted from P. aeruginosa strains isolated from the
lungs of two CF patients with severe lung disease (SE4 and SE22)
and lipid A structures analysed by negative ion matrix-assisted
laser desorption ionization time-of-flight (MALDI-TOF) mass
spectrometry (MS). LPS was purified by Mg
2+–ethanol precipita-
tion as described by Darveau and Hancock [34] after growth in
lysogenic broth supplemented with 1 mM MgCl2 at 37uC.
Individual LPS samples were additionally extracted to remove
contaminating phospholipids [35] and TLR2 contaminating
proteins [36]. Lipid A was isolated after hydrolysis in 1% SDS
at pH 4.5 as described [37]. Briefly, 500 ml of 1% SDS in 10 mM
Na-acetate, pH 4.5 was added to a lyophilized sample. Samples
were incubated at 100uC for 1 h, frozen, and lyophilised. The
dried pellets were resuspended in 100 ml of water and 1 ml of
acidified ethanol (100 ml 4 N HCl in 20 ml 95% EtOH). Samples
were centrifuged at 5,000 rpm for 5 minutes. The lipid A pellet
was further washed (36) in 1 ml of 95% EtOH. The entire series
of washes was repeated twice. Samples were resuspended in 500 ml
of water, frozen on dry ice and lyophilised. MALDI-TOF MS
experiments were performed as described for the analysis of LPS
or lipid A preparations with the following modifications [38].
Lyophilized lipid A was dissolved with 10 ml 5-chloro-2-mercap-
tobenzothiazole (CMBT) MALDI matrix in chloroform/metha-
nol, 1:1 (v/v), and then applied (1 ml) onto the sample plate. All
MALDI-TOF experiments were performed using a Bruker
Autoflex III MALDI-TOF mass spectrometer (Bruker Daltonics
Inc., Billerica, MA). Each spectrum was an average of 200 shots.
ES Tuning Mix (Agilent, Palo Alto, CA) was used to calibrate the
MALDI-TOF MS. Commercially available P. aeruginosa LPS
(serotype 10) has a penta-acylated structure (data not shown). In
contrast, SE4 and SE22 isolates from CF patients synthesise hexa-
and hepta-acylated LPS, respectively [39].
Cell culture and treatment
THP-1 human acute monocytic leukemia cell line was obtained
from the European Collection of Cell Cultures and cultured
routinely in RPMI supplemented with 10% FBS, L-glutamine,
penicillin and streptomycin (Invitrogen, Paisley, UK). Unless
otherwise stated, cells were pre-treated with LL-37 (10 mg/ml) for
1 h before stimulation with LPS for 24 h for ELISA. For Western
blotting experiments, cells were pre-treated with LL-37 for 1 h and
subsequently stimulated with LPS for 0–120 min as indicated in
the figure legends. In some experiments, cells were washed with
PBS after the 1 h pre-treatment with LL-37 and then stimulated
with LPS as indicated.
Western blotting
THP-1 cells were treated as described above and cytoplasmic
extracts were prepared as described previously [40]. Protein
concentrations of extracts were determined and equal concentra-
tions of samples were separated on 10% SDS-polyacrylamide gels
and transferred onto 0.2 mm nitrocellulose membrane. The
membrane was blocked for 1 h at room temperature with 5%
Marvel or 3% BSA in PBS containing 0.1% Tween 20 (PBST)
according to the antibody manufacturer’s instructions. Cytoplas-
mic extracts were immunoblotted for IkBa,I kBb and phosphor-
ylated forms of IkBa (Ser32/36) and IKKa/b (Ser180/181).
Equal loading of samples was confirmed by immunoblotting for
GAPDH. Proteins were detected using the appropriate HRP-
conjugated secondary antibody and visualised by chemilumines-
cence (GE Healthcare UK, Buckinghamshire, UK) and analysed
using the Syngene GeneSnap and GeneTools software on the
ChemiDoc system.
IL-8 ELISA
IL-8 levels in cell-free supernatants were quantified using a
commercially available ELISA kit (R&D Systems) according to
manufacturer’s instructions.
Sputum processing
Expectorated sputum samples were obtained from CF patients
(n=12) under the Office for Research Ethics Northern Ireland
ethical approval study number 06/NIR01/11. Each sample was
suspended in 86volumes of saline with 1 M DTT and placed on a
roller for 1 h to allow full disruption of the dehydrated mucus. The
Neutralisation of LPS by LL-37
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resultant supernatant stored at 280uC until required for analysis.
Sulphated glycosaminoglycan (sGAG) assay
GAG levels were measured using the Blyscan Blue sGAG assay
as directed by the manufacturer (Biocolour Ltd., Co Antrim,
Northern Ireland). Briefly, sputum and standards were made up as
directed and incubated with 1 ml of Dye Reagent (1,9-dimethy-
methylene blue) for 30 min at room temperature with constant
agitation. Samples were spun at 130006 g for 10 min to pellet
resulting precipitate, which was resuspended in 1 ml of Dissoci-
ation Reagent for 10 min. Samples and standards (200 ml) were
added to a 96 well plate and the absorbance determined at
656 nm and results were expressed as mg/ml.
DNase/ heparinase II treatment of CF sputum
CF sputum was incubated with PulmozymeH (dornase alfa;
recombinant human DNase I, Genentech, USA) and the lyase
heparinase II to cleave DNA fragments and sulphated GAGs,
respectively. CF sputum was incubated with DNase (30 mg/ml)
and/or heparinase II (10 mU) for 1 h at 37uC.
LL-37 ELISA
Total LL-37 levels were measured in treated and untreated CF
sputum by indirect ELISA as previously described with some
modifications [41]. LL-37 standards/samples were added to
GreinerH high binding 96 well plates and dried overnight at
37uC. Plates were washed 3 times with PBST and blocked in
PBST containing 1% BSA for 1 h at room temperature. Rabbit
anti-LL-37 antibody was added to the plate for 2 h (100 ml/well,
1:10,000). Plates were washed 3 times with PBST and 100 mlo f
HRP-conjugated goat anti-rabbit antibody added per well for 1 h
at room temperature. After washing, peroxidase activity was
measured by the addition of ABTS substrate (Invitrogen) and
reading the absorbance at 405 nm on a microtitre plate reader
(Genios using Magellan software).
LPS-binding assay
The ability of LL-37 present in treated and untreated CF
sputum to bind LPS was analysed by ELISA as previously
described with some modifications [42]. Briefly, GreinerH high
binding 96 well plates were coated with 100 ng/well of LPS
diluted in serum free media (SFM) and incubated at 37uC for at
least 3 h. The wells were washed 3 times with distilled water before
air-drying overnight at room temperature. Plates were blocked
with 1% BSA in PBST for at least 1 h at room temperature.
Standards and sputum samples were made up to 100 ml in SFM
and incubated on the plate at 37uC for 2 h. All samples were
loaded in duplicate and diluted in a 1:2 dilution series. After
washing 3 times with PBST, rabbit anti-LL-37 antibody was
added to the plate for 2 h at room temperature (100 ml/well,
1:10,000). Plates were again washed and 100 ml of HRP-
conjugated goat anti-rabbit antibody added per well for 2 h at
room temperature. Peroxidase activity was measured and
quantified as described above.
LPS Neutralisation Assay
The ability of LL-37 present in treated and untreated CF
sputum to inhibit LPS-induced IL-8 production by THP-1
monocytic cells was analysed by a modification of the above
LPS-binding ELISA protocol. LPS was immobilised in GreinerH
high binding 96 well plates as described above. The wells were
washed 3 times with SFM before samples were added. CF sputum
samples (n=12) were treated with PulmozymeH DNase and/or
heparinase II as described previously in the absence or presence of
rabbit anti-LL-37 antibody (1 mg/ml) or heat-inactivated (HI)
antibody as a negative control. Sputum samples were made up to
100 ml in SFM and incubated on the plate at RT for 1 h. After
washing 3 times with SFM, THP-1 cells (1610
6/ml) were added to
each well and incubated for 6 h at 37uC. Cells were then collected
and IL-8 levels in cell free supernatants were determined by
ELISA.
Statistical Analyses
All statistical analyses were performed using GraphPad PRISM
5.0 software package (San Diego, CA). Results are expressed as the
mean 6 SEM and unless specified otherwise all results are
representative of at least three independent experiments per-
formed in duplicate. Differences between multiple treatments were
compared by one-way analysis of variance (ANOVA) followed by
Bonferroni’s Multiple Comparison post test. A p value of ,0.05
was considered to represent a statistically significant difference
(* p,0.05; ** p,0.01; *** p,0.001).
Results
LL-37 exerts potent anti-endotoxin effects in THP-1
monocytes
The ability of LL-37 to inhibit LPS-induced pro-inflammatory
cytokine production is well documented. As shown in Figure 1A,
pre-treatment with LL-37 significantly inhibited commercially
available P. aeruginosa LPS-induced IL-8 production from THP-1
human monocytic cells by approximately 90%. Investigation of
upstream regulators of IL-8 production revealed that pre-treating
monocytes with LL-37 down-regulated the LPS-induced NF-kB
pathway, as illustrated in Figure 1B. Stimulation of THP-1 cells
with LPS resulted in the almost complete degradation of the
inhibitory proteins IkBa and IkBb by 60 and 120 min,
respectively, compared to control cells. Pre-treatment of cells with
LL-37 inhibited this degradation at corresponding time points.
Degradation of IkB proteins in response to a pro-inflammatory
stimulus such as LPS occurs after their phosphorylation, which is
regulated by kinases such as IKKa/b. Phosphorylation of IkBa
(Ser32/36) was observed following LPS stimulation and this
phosphorylation was inhibited by LL-37. In addition, phosphor-
ylation of IKKa/b (Ser180/181) was similarly induced by LPS
stimulation compared to control cells, and again, this phosphor-
ylation event was inhibited by LL-37 pre-treatment.
Removal of exogenous LL-37 after pre-treatment
diminishes its anti-inflammatory activities
In order to investigate whether the ability of LL-37 to inhibit
LPS-induced signalling was dependent on its presence in the cell
culture media at the time of LPS stimulation, experiments were
performed in which THP-1 monocytes were pre-treated with LL-
37 (10 mg/ml) for 1 h and then washed 3 times with sterile PBS to
remove exogenous peptide. The cells were then stimulated with
0.01, 0.1 and 1 mg/ml LPS and IL-8 levels were measured in cell
free supernatants after 24 h (Figure 2A). In contrast to the
pronounced inhibition of LPS-induced IL-8 production we
observed in Figure 1A, when the cells were washed to remove
exogenous LL-37 prior to LPS stimulation no significant inhibition
was observed when compared to LPS alone, regardless of
concentration of LPS used (Figure 2A) of whether cells were
pre-treated for 1 h or 2 h prior to washing (data not shown). In
agreement with previous work, our results demonstrate that the
sustained presence of LL-37 at the time of stimulation is necessary
Neutralisation of LPS by LL-37
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[43]. Furthermore, washing the cells prior to stimulation
diminished the ability of LL-37 to inhibit LPS-induced IkBa
degradation (Figure 2B) that was previously observed in Figure 1B.
LL-37 potently inhibits IL-8 production induced by
clinical P. aeruginosa LPS isolates from CF patients
Our findings to date highlight the importance of direct
interaction between LPS and LL-37 in mediating its maximal
anti-endotoxin activities in response to commercially available P.
aeruginosa LPS formulations. Although, the contribution of LPS to
pathogenesis varies depending on a number of factors, unique lipid
A modifications that occur in clinical P. aeruginosa CF isolates are
associated with CF lung infection [39,44,45]. TLR4-mediated
responses are highly dependent on the level of acylation of the lipid
A structure of LPS. P. aeruginosa synthesizes more highly acylated
LPS structures during adaptation to the CF airway environment
[34,45–47]. Although such modifications can confer resistance to
cationic AMPs such as C18G and polymyxin [44], their effect on
the ability of LL-37 to neutralise the modified LPS is unknown.
Therefore, to evaluate the effect of LL-37 on the IL-8 inducing
ability of such LPS preparations, THP-1 monocytes were pre-
treated with LL-37 (5 mg/ml) for 1 h prior to stimulation with LPS
extracted from P. aeruginosa strains isolated from the lungs of two
CF patients with severe lung disease (SE4 and SE22) for 24 h.
Commercially available P. aeruginosa LPS (serotype 10) has a penta-
acylated structure (data not shown), whereas SE4 and SE22 LPS
isolates from CF patients synthesise hexa- and hepta-acylated LPS,
respectively [39].
As shown in Figure 3A and 3B, both LPS preparations
significantly induced THP-1 monocyte IL-8 production when
compared to untreated control cells in a dose-dependent manner.
LL-37 pre-treatment significantly inhibited induction of IL-8 by
the LPS isolates at each concentration of LPS (.90%). These
findings demonstrate that acylation of the lipid A component of P.
aeruginosa LPS does not affect the ability of LL-37 to neutralise and
inhibit LPS-induced IL-8 production from human monocytic cells.
Similar to what was observed for commercial P. aeruginosa LPS in
Figure 2A, there was no significant difference between LPS and
LPS+LL-37 when the cells were washed following LL-37 pre-
treatment (Figure 3C and 3D). In contrast, with continued
presence of LL-37, IL-8 production was inhibited .90%. Overall,
these findings again support previous observations that the
sustained presence of LL-37 at the time of stimulation is necessary
for maximal anti-endotoxin effect regardless of LPS source.
GAGs and DNA present in the CF lung abrogate the
ability of LL-37 to neutralise LPS
LL-37 has previously been demonstrated to bind to GAGs and
DNA and such interactions negatively impact on the antimicrobial
activity of LL-37 [19,26]. In agreement with previous data
[48,49], GAG levels were found to be significantly elevated in the
CF lung (328631 mg/ml) compared to healthy controls (not
detectable). Given the importance of a physical interaction
between LL-37 and LPS for the peptide to inhibit LPS signalling,
we investigated the status and LPS-binding ability of LL-37 in CF
sputa treated with DNase and/or the lyase heparinase II.
Heparinase II was used to degrade polysaccharide GAGs as it
possesses the broadest known substrate specificity of the hepari-
nases [50]. Treatment with DNase or heparinase II alone induced
a slight, increase in total LL-37 levels compared to untreated CF
sputum (Figure 4A). However, a combination treatment of both
DNase and heparinase II significantly increased the amount of LL-
37 detectable in CF sputum when compared to untreated CF
sputum samples. With this increase in liberated LL-37, a
concomitant significant increase in LPS-binding was also observed
(Figure 4B) in DNase- and heparinase II-treated CF sputum.
The increased level and concomitant LPS-binding activity of
LL-37 caused by DNase and heparinase II treatment of CF sputa
resulted in functional LPS-neutralising activity as shown in
Figure 5. Our findings demonstrate that treatment of CF sputum
with DNase and heparinase II was associated with a significant
decrease in the amount of LPS-induced IL-8 produced by THP-1
cells when compared to untreated sputum. The inclusion of a
specific anti-LL-37 antibody demonstrates that a significant
proportion of this inhibition was mediated by liberated LL-37
present in the treated sputum, an effect that was negated when the
antibody was heat-inactivated.
Discussion
P. aeruginosa can take advantage of the compromised health of
susceptible individuals including CF patients, and initiate an
Figure 1. LL-37 inhibits LPS-induced IL-8 production and IkB
degradation in THP-1 monocytic cells. (A) THP-1 monocytes were
pre-treated for 1 h with 10 mg/ml LL-37 and incubated in the absence
or presence of 1 mg/ml P. aeruginosa LPS. After 24 h stimulation with
LPS, IL-8 levels were quantified in cell-free culture supernatants by
ELISA. *** p,0.001; Con, control. (B) Cytoplasmic extracts were
prepared following 30, 60 and 120 min and levels of IkBa,I kBb,
phosphorylation of IkBa (Ser32/36) and IKKa/b (Ser180/181) were
determined by Western blotting. GAPDH was used to control for
protein loading.
doi:10.1371/journal.pone.0026525.g001
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monocytes were pre-treated with 5 mg/ml LL-37 for 1 h before cells were stimulated for 24 h with (A) SE4 and (B) SE22 LPS isolates from CF patients
with severe airway disease (1, 10 and 100 ng/ml). IL-8 levels in cell-free culture supernatants were quantified by ELISA. ** p,0.01; *** p,0.001
compared to corresponding LPS alone (- LL-37). THP-1 monocytes were pre-treated for 1 h with LL-37 (5 mg/ml) and then washed with sterile PBS to
remove extracellular, non-incorporated, exogenous LL-37. The cells were resuspended in fresh media and stimulated with 50 ng/ml (C) SE4 and (D)
SE22 LPS for 24 h. IL-8 levels in cell-free culture supernatants were quantified by ELISA. Results are expressed as percentage of control response
(100%=LPS alone). *** p,0.001.
doi:10.1371/journal.pone.0026525.g003
Figure 2. Removal of exogenous LL-37 prior to LPS stimulation diminishes its anti-endotoxin activity. (A) THP-1 monocytes were pre-
treated for 1 h with LL-37 (10 mg/ml) and then washed with sterile PBS to remove extracellular, non-incorporated, exogenous LL-37. The cells were
resuspended in fresh media and stimulated with 0.01, 0.1 and 1 mg/ml LPS for 24 h. IL-8 levels in cell-free culture supernatants were quantified by
ELISA. (B) THP-1 monocytes were pre-treated for 1 h with 10 mg/ml LL-37 and washed as described previously. Following resuspension, cells were
stimulated with 1 mg/ml LPS for 30, 60 and 120 min. Cytoplasmic extracts were prepared and IkBa levels were determined by Western blotting.
GAPDH was used to control for protein loading.
doi:10.1371/journal.pone.0026525.g002
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significantly to morbidity and mortality of infected patients. P.
aeruginosa LPS is a prominent factor in mediating both bacterial
virulence and host responses [33]. In this study, we show that
exogenous LL-37 inhibits P. aeruginosa LPS-induced IL-8 produc-
tion. This potent knockdown of IL-8 production was associated
with downregulation of the activity of a number of transcription
factors such as NF-kB and also AP-1, STAT-1 and IRF-3 (data
not shown). However, removal of exogenous LL-37 prior to LPS
stimulation abolished these inhibitory effects. These findings
suggest that a primary mechanism by which LL-37 inhibits LPS
signalling is via neutralisation of LPS extracellularly. The ability of
LL-37 to neutralise/detoxify LPS from a number of species, such
as E. coli, Burkholderia cepacia and Salmonella typhimurium, has been
well characterised [28–32]. Binding studies with LL-37 revealed
that LL-37 binds with high affinity to E. coli LPS and with a
stoichiometry of ,1:1 [13,29]. Furthermore, LL-37 binds to LPS
in solution and also when LPS is already bound to macrophages
[29]. Published work to date suggests at least three mechanisms by
which LL-37 may detoxify LPS: (1) LL-37 binds directly to LPS
making it unavailable for LPS binding protein (LBP) and transfer
to the primary LPS receptor – CD14; (2) LL-37 binds directly to
CD14, and (3) LL-37 dissociates LPS oligomers preventing LPS
from binding to LBP or CD14 [28–30,51].
LPS possesses three structural domains, lipid A, core oligosac-
charide, and O polysaccharides. The activation mechanism of LPS
is initiated when lipid A binds to LPS-binding protein (LBP),
which accelerates the binding of LPS to CD14. P. aeruginosa
synthesizes more highly acylated lipid A structures during
adaptation to the CF airway environment and the acylation state
of LPS may alter TLR4-mediated responses [44–47]. In agree-
ment with previous findings [44], THP-1 monocytes stimulated
with LPS extracted from P. aeruginosa strains isolated from
chronically-infected lungs of CF patients secreted higher amounts
of IL-8 than cells stimulated with commercially available P.
aeruginosa LPS at comparable concentrations demonstrating
heightened activation of pro-inflammatory responses which is
associated with more highly acylated forms of P. aeruginosa LPS. In
addition to increased inflammation, these modifications are
associated with resistance to cationic AMPs such as C18G and
polymyxin [44]. However, in this study we show that LL-37
retains its ability to neutralise such highly acylated forms of LPS
suggesting that this AMP could play a significant role in
dampening LPS-induced inflammation in the CF lung. The
ability of LL-37 to exert its antibacterial activity against such
strains remains to be determined.
As an AMP, LL-37 displays antibacterial activity against P.
aeruginosa with MICs of 1.3–16 mg/ml reported for various strains
[11,13]. Furthermore, a low concentration of LL-37 (0.5 mg/ml)
potently inhibited the formation of P. aeruginosa biofilm [17]. These
findings are of particular relevance to CF as P. aeruginosa is the
most prevalent and destructive pulmonary pathogen in patients
and biofilm formation is a crucial factor in chronic infection due to
their inherent resistance to antimicrobial agents [17]. However, in
the complex milieu of the CF lung, it appears that the antibacterial
activity of LL-37 is diminished through interactions with various
components of the lung environment such as DNA and GAGs
[19,26]. The number of neutrophils in the CF lung is estimated at
least two orders of magnitude higher than patients with chronic
bronchitis during a period of exacerbation [52]. In addition to LL-
37, levels of GAGs, DNA and LPS in the CF lung also correlate
with neutrophilia and/or neutrophil elastase activity [9,10,26,52–
54]. Furthermore, levels of GAGs such as heparin sulphate and
chondroitin sulphate are markedly increased in CF bronchial
tissue and sputum [48,49,55].
Polyanionic molecules such as GAGs and DNA are able to bind
positively charged peptides including LL-37 in a charge-based
interaction. Previous work has found that treatment of CF lung
secretions with DNase and GAG lyases increased the levels of free
LL-37, in addition to the bactericidal activity of samples [19,26].
In concurrence with previous work, we show that the interaction
of LL-37 with these molecules in the pulmonary environment of
the CF lung also negates the ability of LL-37 to bind and thereby
neutralise LPS. Our findings demonstrate decreased levels of LL-
37 and LL-37-related LPS binding in CF sputum as a result of
binding to GAGs and DNA. However, upon removal of GAGs
and DNA by treatment with the lyase heparinase II and DNase,
respectively, we were able to simultaneously and synergistically
increase LL-37 levels and LPS-binding activity in CF sputum. In
addition, this increase in LL-37 and LPS binding was associated
with a significant decrease in LPS-induced IL-8 production when
compared to untreated sputum. DNase (PulmozymeH) is the most
widely used mucolytic therapy in patients with CF, reducing
the viscosity of lung secretions and aiding airway clearance.
Figure 4. LL-37 levels and its ability to bind LPS in CF sputum
are increased following treatment with DNase and heparinase
II. (A) CF sputum samples (n=12) were treated with PulmozymeH
DNase and/or heparinase II for 1 h at 37uC. The LL-37 content of these
samples and untreated sputum samples were quantified by ELISA. (B)
The ability of available LL-37 present in untreated and treated CF
sputum samples to bind LPS was determined by ELISA. Results are
expressed as percentage of untreated control (100%=untreated CF
sputum). ** p,0.01; *** p,0.001.
doi:10.1371/journal.pone.0026525.g004
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protein complexes, thereby liberating trapped cationic molecules
like LL-37 [19].
The synergistic increase in both LL-37 levels and concomitant
LL-37:LPS binding when sputum samples were treated with both
DNase and heparinase II indicates that the use of DNase alone
may liberate the peptide leaving it free to bind to GAGs, or vice
versa. In contrast, co-treatment of heparinase II may serve to
cooperatively enhance the activity of DNase, resulting in
decreased total levels of anionic electrolytes and liberation of
LL-37, which then remains free to exert its anti-endotoxin effects.
These results suggest that a combination therapy of DNase and
heparinase II could be explored as a possible treatment strategy for
CF patients. The benefits of such a treatment could include a
much greater decrease in lung secretion viscosity and thereby
enhanced clearance, increased bacterial killing capacity within the
mucosal layer, and a reduction in the inflammatory response
generated by the massive LPS load in the CF lung. As GAGs are
constituents of the lung extracellular matrix and therefore play an
important role in lung function and homeostasis, alterations in
their synthesis and degradation may affect lung pathology and
understanding the changes in GAG expression that occur in lung
diseases such as CF may lead to novel targets for pharmacological
intervention [56]. Although GAG lyases from F. heparinum are
presently being developed for therapeutic applications [57], their
role in CF has not yet been explored.
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